CLINICAL STUDY: ACUTE CORONARY SYNDROMES/INFARCTION
Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/NonST-elevation myocardial infarction
B-type natriuretic peptide and prognosis in TACTICS-TIMI 18
David A. Morrow, MD, MPH*,*,
James A. de Lemos, MD ,
Marc S. Sabatine, MD, MPH*,
Sabina A. Murphy, MPH ,
Laura A. Demopoulos, MD ,
Peter M. DiBattiste, MD ,
Carolyn H. McCabe, BS*,
C. Michael Gibson, MD, MS, FACC ,
Christopher P. Cannon, MD, FACC* and
Eugene Braunwald, MD, FACC*
* Cardiovascular Division, Department of Medicine, Brigham & Womens Hospital, Boston, Massachusetts, USA
Donald W. Reynolds Cardiovascular Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Harvard Clinical Research Institute, Boston, Massachusetts, USA
Merck & Co, West Point, Pennsylvania, USA
Manuscript received October 27, 2002;
revised manuscript received December 4, 2002,
accepted December 26, 2002.
* Reprint requests and correspondence: Dr. David A. Morrow, Cardiovascular Division, Brigham and Womens Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA. dmorrow{at}partners.org
OBJECTIVES: This study was designed to evaluate B-type natriuretic peptide (BNP) for risk assessment and clinical decision making over a range of cut points, alone and with cardiac troponin I (cTnI), in patients with nonST-elevation acute coronary syndromes (ACS).
BACKGROUND: B-type natriuretic peptide holds promise for risk stratification. Additional evidence regarding optimal decision limits, use in combination with troponin, and use in targeting therapy is needed before acceptance into clinical use for ACS.
METHODS: We evaluated BNP at baseline in 1,676 patients with nonST-elevation ACS randomized to early invasive versus conservative management.
RESULTS: Patients with elevated BNP (>80 pg/ml; n = 320) were at higher risk of death at seven days (2.5% vs. 0.7%, p = 0.006) and six months (8.4% vs. 1.8%, p < 0.0001). The association between BNP and mortality at six months (adjusted odds ratio [OR] 3.3; 95% confidence interval [CI] 1.7 to 6.3) was independent of important clinical predictors, including cTnI and congestive heart failure (CHF). Patients with elevated BNP had a fivefold higher risk of developing new CHF by 30 days (5.9% vs. 1.0%, p < 0.0001). B-type natriuretic peptide added prognostic information to cTnI, discriminating patients at higher mortality risk among those with negative (OR 6.9; 95% CI 1.9 to 25.8) and positive (OR 4.1; 95% CI 1.9 to 9.0) baseline cTnI results. No difference was observed in the effect of invasive versus conservative management when stratified by baseline levels of BNP (pinteraction 0.6).
CONCLUSIONS: Elevated BNP (>80 pg/ml) at presentation identifies patients with nonST-elevation ACS who are at higher risk of death and CHF and adds incremental information to cTnI. Additional work is needed to identify therapies that may reduce the risk associated with increased BNP.
|
Abbreviations and Acronyms
| | ACS | | acute coronary syndrome(s) | | BNP | | B-type natriuretic peptide | | CHF | | congestive heart failure | | CI | | confidence interval | | CK-MB | | creatine kinase-MB | | cTnI | | cardiac troponin I | | HF | | heart failure | | MI | | myocardial infarction | | NSTEMI | | nonST-elevation myocardial infarction | | OR | | odds ratio | | TIMI | | Thrombolysis In Myocardial Infarction | | UA | | unstable angina |
|
This article has been cited by other articles:

|
 |

|
 |
 
D S C Ang, L Wei, M P C Kao, C C Lang, and A D Struthers
A comparison between B-type natriuretic peptide, Global Registry of Acute Coronary Events (GRACE) score and their combination in ACS risk stratification
Heart,
November 15, 2009;
95(22):
1836 - 1842.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Montalescot, H. Drexler, R. Gallo, T. Pearson, M. Thoenes, and D. L. Bhatt
Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study
Eur. Heart J.,
November 2, 2009;
30(22):
2733 - 2741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Kurl, M Ala-Kopsala, H Ruskoaho, T Makikallio, K Nyyssonen, O Vuolteenaho, J Sivenius, J T Salonen, and J A Laukkanen
Plasma N-terminal fragments of natriuretic peptides predict the risk of stroke and atrial fibrillation in men
Heart,
July 1, 2009;
95(13):
1067 - 1071.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. W. Hamm, H. Möllmann, J.-P. Bassand, and F. van de Werf
CHAPTER 16 Acute Coronary Syndromes
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Bonaca and D. A. Morrow
Defining a Role for Novel Biomarkers in Acute Coronary Syndromes
Clin. Chem.,
September 1, 2008;
54(9):
1424 - 1431.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Fox, S. K. Shernan, C. D. Collard, K.-Y. Liu, S. F. Aranki, S. M. DeSantis, P. Jarolim, and S. C. Body
Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting.
J. Thorac. Cardiovasc. Surg.,
August 1, 2008;
136(2):
452 - 461.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Mega, D. A. Morrow, J. A. de Lemos, S. Mohanavelu, C. P. Cannon, and M. S. Sabatine
Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes.
J. Am. Coll. Cardiol.,
June 24, 2008;
51(25):
2422 - 2429.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Morrow, M. S. Sabatine, M.-L. Brennan, J. A. de Lemos, S. A. Murphy, C. T. Ruff, N. Rifai, C. P. Cannon, and S. L. Hazen
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
Eur. Heart J.,
May 1, 2008;
29(9):
1096 - 1102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Weber, O. Bazzino, J. L. Navarro Estrada, J. J. Fuselli, F. Botto, D. Perez de Arenaza, H. Mollmann, H. N. Nef, A. Elsasser, and C. W. Hamm
N-Terminal B-Type Natriuretic Peptide Assessment Provides Incremental Prognostic Information in Patients With Acute Coronary Syndromes and Normal Troponin T Values Upon Admission
J. Am. Coll. Cardiol.,
March 25, 2008;
51(12):
1188 - 1195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Schnabel, C. M. Messow, E. Lubos, C. Espinola-Klein, H. J. Rupprecht, C. Bickel, C. Sinning, S. Tzikas, T. Keller, S. Genth-Zotz, et al.
Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study
Eur. Heart J.,
March 1, 2008;
29(5):
649 - 657.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Kandil, J. Burack, A. Sawas, H. Bibawy, A. Schwartzman, M. E. Zenilman, and M. H. Bluth
B-Type Natriuretic Peptide: A Biomarker for the Diagnosis and Risk Stratification of Patients With Septic Shock
Arch Surg,
March 1, 2008;
143(3):
242 - 246.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A Pascual-Figal, M. J Antolinos, A. Bayes-Genis, T. Casas, F. Nicolas, and M. Valdes
B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans
Heart,
September 1, 2007;
93(9):
1077 - 1080.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
e1 - e157.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
652 - 726.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Mueller
The Use of B-Type Natriuretic Peptides in Coronary Artery Disease: Utile or Futile?
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
215 - 216.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Ahmed, S. Zafar, A. Y. Alam, N. Ahktar, M. A. Shah, and M. A. Alpert
Plasma Levels of B-Type Natriuretic Peptide in Patients With Unstable Angina Pectoris or Acute Myocardial Infarction: Prognostic Significance and Therapeutic Implications
Angiology,
June 1, 2007;
58(3):
269 - 274.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Circulation,
April 3, 2007;
115(13):
e356 - e375.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Lorgis, M. Zeller, G. Dentan, P. Sicard, M. Jolak, I. L'Huillier, M. Vincent-Martin, J.C. Beer, H. Makki, P. Gambert, et al.
High levels of N-terminal pro B-type natriuretic peptide are associated with ST resolution failure after reperfusion for acute myocardial infarction
QJM,
April 1, 2007;
100(4):
211 - 216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Clin. Chem.,
April 1, 2007;
53(4):
552 - 574.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Bibbins-Domingo, R. Gupta, B. Na, A. H. B. Wu, N. B. Schiller, and M. A. Whooley
N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart Disease
JAMA,
January 10, 2007;
297(2):
169 - 176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. James, J. Lindback, J. Tilly, A. Siegbahn, P. Venge, P. Armstrong, R. Califf, M. L. Simoons, L. Wallentin, and B. Lindahl
Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality Benefit From Coronary Revascularization in Acute Coronary Syndromes: A GUSTO-IV Substudy
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1146 - 1154.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. O'Donoghue, J. A. de Lemos, D. A. Morrow, S. A. Murphy, J. L. Buros, C. P. Cannon, and M. S. Sabatine
Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes
Circulation,
August 8, 2006;
114(6):
550 - 557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Jaffe, L. Babuin, and F. S. Apple
Biomarkers in Acute Cardiac Disease: The Present and the Future
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hammerer-Lercher, R. Geiger, J. Mair, C. Url, G. Tulzer, E. Lechner, B. Puschendorf, and R. Sommer
Utility of N-Terminal Pro-B-Type Natriuretic Peptide to Differentiate Cardiac Diseases from Noncardiac Diseases in Young Pediatric Patients
Clin. Chem.,
July 1, 2006;
52(7):
1415 - 1419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Scirica, D. A. Morrow, C. P. Cannon, K. K. Ray, M. S. Sabatine, P. Jarolim, A. Shui, C. H. McCabe, E. Braunwald, and for the PROVE IT-TIMI 22 Investigators
Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT-TIMI 22 Study
J. Am. Coll. Cardiol.,
June 6, 2006;
47(11):
2326 - 2331.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Vasan
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Circulation,
May 16, 2006;
113(19):
2335 - 2362.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Laukkanen, S. Kurl, M. Ala-Kopsala, O. Vuolteenaho, H. Ruskoaho, K. Nyyssonen, and J. T. Salonen
Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men
Eur. Heart J.,
May 2, 2006;
27(10):
1230 - 1237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Body and C. Roberts
Brain natriuretic peptide as a potential marker of acute coronary syndromes
Emerg. Med. J.,
May 1, 2006;
23(5):
403 - 407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Morrow
Prognostic Value of B-Type Natriuretic Peptide in Unstable Coronary Artery Disease--Reply
JAMA,
April 26, 2006;
295(16):
1895 - 1896.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Morrow, J. A. de Lemos, M. A. Blazing, M. S. Sabatine, S. A. Murphy, P. Jarolim, H. D. White, K. A. A. Fox, R. M. Califf, E. Braunwald, et al.
Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery Disease
JAMA,
December 14, 2005;
294(22):
2866 - 2871.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Ginsburg, M. P. Donahue, and L. K. Newby
Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1615 - 1627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Mitchell, M. D. Brown, I. B.A. Menown, and J. A. Kline
Novel Protein Markers of Acute Coronary Syndrome Complications in Low-Risk Outpatients: A Systematic Review of Potential Use in the Emergency Department
Clin. Chem.,
November 1, 2005;
51(11):
2005 - 2012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ndrepepa, S. Braun, K. Niemoller, J. Mehilli, N. von Beckerath, O. von Beckerath, W. Vogt, A. Schomig, and A. Kastrati
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Patients With Chronic Stable Angina
Circulation,
October 4, 2005;
112(14):
2102 - 2107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schillinger
Editorial Comment--Brain Natriuretic Peptide and Early Cardiac Dysfunction After Subarachnoid Hemorrhage
Stroke,
July 1, 2005;
36(7):
1570 - 1571.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.M. Makikallio, T.H. Makikallio, J.T. Korpelainen, O. Vuolteenaho, J.M. Tapanainen, K. Ylitalo, K.A. Sotaniemi, H.V. Huikuri, and V.V. Myllyla
Natriuretic Peptides and Mortality After Stroke
Stroke,
May 1, 2005;
36(5):
1016 - 1020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schillinger
Cardiovascular Risk Stratification in Older Patients: Role of Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels
JAMA,
April 6, 2005;
293(13):
1667 - 1669.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Kragelund, B. Gronning, L. Kober, P. Hildebrandt, and R. Steffensen
N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease
N. Engl. J. Med.,
February 17, 2005;
352(7):
666 - 675.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Jarai, N. Iordanova, R. Jarai, A. Raffetseder, W. Woloszczuk, M. Gyongyosi, G. Geyer, J. Wojta, and K. Huber
Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide
Eur. Heart J.,
February 1, 2005;
26(3):
250 - 256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bassan, A. Potsch, A. Maisel, B. Tura, H. Villacorta, M. V. Nogueira, A. Campos, R. Gamarski, A. C. Masetto, and M. A. Moutinho
B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation
Eur. Heart J.,
February 1, 2005;
26(3):
234 - 240.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Silva, A. W. Chan, C. J. White, T. J. Collins, J. S. Jenkins, J. P. Reilly, and S. R. Ramee
Elevated Brain Natriuretic Peptide Predicts Blood Pressure Response After Stent Revascularization in Patients With Renal Artery Stenosis
Circulation,
January 25, 2005;
111(3):
328 - 333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Gluckman, M. Sachdev, S. P. Schulman, and R. S. Blumenthal
A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes
JAMA,
January 19, 2005;
293(3):
349 - 357.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Sabatine, D. A. Morrow, J. A. de Lemos, T. Omland, M. Y. Desai, M. Tanasijevic, C. Hall, C. H. McCabe, and E. Braunwald
Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia
J. Am. Coll. Cardiol.,
November 16, 2004;
44(10):
1988 - 1995.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Jarai, R. Jarai, and K. Huber
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease
J. Am. Coll. Cardiol.,
November 2, 2004;
44(9):
1932 - 1932.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Jernberg, S. James, B. Lindahl, N. Johnston, M. Stridsberg, P. Venge, and L. Wallentin
Natriuretic peptides in unstable coronary artery disease
Eur. Heart J.,
September 1, 2004;
25(17):
1486 - 1493.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Rodeheffer
Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?
J. Am. Coll. Cardiol.,
August 18, 2004;
44(4):
740 - 749.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sadanandan, C. P. Cannon, K. Chekuri, S. A. Murphy, P. M. DiBattiste, D. A. Morrow, J. A. de Lemos, E. Braunwald, and C. M. Gibson
Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction
J. Am. Coll. Cardiol.,
August 4, 2004;
44(3):
564 - 568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. I. Larsen and K. Dickstein
BNP in acute coronary syndromes: the heart expresses its suffering
Eur. Heart J.,
August 1, 2004;
25(15):
1284 - 1286.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Mega, D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. A. Murphy, N. Rifai, C. M. Gibson, E. M. Antman, and E. Braunwald
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI-23 substudy
J. Am. Coll. Cardiol.,
July 21, 2004;
44(2):
335 - 339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Galvani, F. Ottani, L. Oltrona, D. Ardissino, G. F. Gensini, A. P. Maggioni, P. M. Mannucci, N. Mininni, M. D. Prando, M. Tubaro, et al.
N-Terminal Pro-Brain Natriuretic Peptide on Admission Has Prognostic Value Across the Whole Spectrum of Acute Coronary Syndromes
Circulation,
July 13, 2004;
110(2):
128 - 134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Schenk, P. M. McCarthy, R. C. Starling, K. J. Hoercher, M. D. Hail, Y. Ootaki, G. S. Francis, K. Doi, J. B. Young, and K. Fukamachi
Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy
J. Thorac. Cardiovasc. Surg.,
July 1, 2004;
128(1):
38 - 43.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Bazzino, J. J Fuselli, F. Botto, D. Perez de Arenaza, C. Bahit, J. Dadone, and for the PACS group of investigators
Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes
Eur. Heart J.,
May 2, 2004;
25(10):
859 - 866.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Galvani, D. Ferrini, and F. Ottani
Natriuretic peptides for risk stratification of patients with acute coronary syndromes
Eur J Heart Fail,
March 15, 2004;
6(3):
327 - 333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Wang, M. G. Larson, D. Levy, E. J. Benjamin, E. P. Leip, T. Omland, P. A. Wolf, and R. S. Vasan
Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death
N. Engl. J. Med.,
February 12, 2004;
350(7):
655 - 663.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Clerico and M. Emdin
Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review
Clin. Chem.,
January 1, 2004;
50(1):
33 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. D. White and J. K. French
Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes
J. Am. Coll. Cardiol.,
December 3, 2003;
42(11):
1917 - 1920.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Morrow and E. Braunwald
Future of Biomarkers in Acute Coronary Syndromes: Moving Toward a Multimarker Strategy
Circulation,
July 22, 2003;
108(3):
250 - 252.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
BNP Identifies High-Risk ACS, But Its Clinical Utility Is Unclear
Journal Watch Emergency Medicine,
May 27, 2003;
2003(527):
8 - 8.
[Full Text]
|
 |
|
|